197 related articles for article (PubMed ID: 37457709)
1. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.
Pan B; Cheng X; Tan W; Liu R; Wu X; He J; Fan Q; Zhang Y; Cheng J; Deng Y
Front Immunol; 2023; 14():1188256. PubMed ID: 37457709
[TBL] [Abstract][Full Text] [Related]
2. High expression of integrin-binding sialoprotein (IBSP) is associated with poor prognosis of osteosarcoma.
Ma Y; Chen B; Zhang B; Zhang C; Zhu Q; Wang X; Liu Z; Liu H
Aging (Albany NY); 2023 Nov; 16(1):28-42. PubMed ID: 38006395
[TBL] [Abstract][Full Text] [Related]
3. Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma.
Wang Q; Zhang W; Guo Y; Li Y; Fu K
Aging (Albany NY); 2021 Nov; 13(21):24155-24170. PubMed ID: 34747719
[TBL] [Abstract][Full Text] [Related]
4. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma.
Ma C; Nie XG; Wang YL; Liu XH; Liang X; Zhou QL; Wu DP
Mol Med Rep; 2019 May; 19(5):4205-4212. PubMed ID: 30942427
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.
Liu Z; Liu B; Feng C; Li C; Wang H; Zhang H; Liu P; Li Z; He S; Tu C
Front Immunol; 2022; 13():1071636. PubMed ID: 36569869
[TBL] [Abstract][Full Text] [Related]
6. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
[TBL] [Abstract][Full Text] [Related]
7. Necrotizing apoptosis-related genes prognosis and treatment effect analysis of osteosarcoma in children.
Chen Y; Wu L; Li Y; Zheng J; Zhong S; Gu S; Chen J
J Gene Med; 2024 Jan; 26(1):e3646. PubMed ID: 38100138
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
9. A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.
Tang H; Liu S; Luo X; Sun Y; Li X; Luo K; Liao S; Li F; Liang J; Zhan X; Wei Q; Liu Y; He M
Front Immunol; 2023; 14():1150588. PubMed ID: 37090691
[TBL] [Abstract][Full Text] [Related]
10. Osteosarcoma-Associated Immune Genes as Potential Immunotherapy and Prognosis Biomarkers.
Yang L; Long Y; Xiao S
Biochem Genet; 2024 Apr; 62(2):798-813. PubMed ID: 37452172
[TBL] [Abstract][Full Text] [Related]
11. KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.
Guo X; Zhou L; Wu Y; Li J
Oxid Med Cell Longev; 2022; 2022():2764940. PubMed ID: 36742345
[TBL] [Abstract][Full Text] [Related]
12. PTBP1 as a Promising Predictor of Poor Prognosis by Regulating Cell Proliferation, Immunosuppression, and Drug Sensitivity in SARC.
Gong H; Jiang A; Jiang R; Wang Y; Zhang D; Wu Z; Xiao J
Oxid Med Cell Longev; 2022; 2022():5687238. PubMed ID: 35651729
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.
Tan J; Feng X; Wu H; Yang B; Shi M; Xie C; Su Z; Li L; Luo M; Zuo Z; Zhu S; Yang J; Lin L
J Immunol Res; 2022; 2022():6568278. PubMed ID: 36065454
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA FER1L4 Suppresses Tumorigenesis by Regulating the Expression of PTEN Targeting miR-18a-5p in Osteosarcoma.
Fei D; Zhang X; Liu J; Tan L; Xing J; Zhao D; Zhang Y
Cell Physiol Biochem; 2018; 51(3):1364-1375. PubMed ID: 30481787
[TBL] [Abstract][Full Text] [Related]
15. PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes.
Li R; Yan L; Jiu J; Liu H; Li D; Li X; Zhang J; Li S; Fan Z; Lv Z; Zhu Y; Wang B
Int J Biol Sci; 2024; 20(4):1452-1470. PubMed ID: 38385075
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
17. CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.
Han Q; Li C; Cao Y; Bao J; Li K; Song R; Chen X; Li J; Wu X
Cancer Med; 2019 Jul; 8(8):3981-3991. PubMed ID: 31150156
[TBL] [Abstract][Full Text] [Related]
18. Carboxypeptidase E is a prognostic biomarker co-expressed with osteoblastic genes in osteosarcoma.
Chen D; Wan B; Cheng Y; Luo Y; Bai X; Guo J; Li G; Jin T; Nie J; Liu W; Wang R
PeerJ; 2023; 11():e15814. PubMed ID: 37663298
[TBL] [Abstract][Full Text] [Related]
19. The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.
Cai L; Lv J; Zhang Y; Li J; Wang Y; Yang H
J Cell Mol Med; 2017 Nov; 21(11):2654-2662. PubMed ID: 28866868
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy.
Xu HG; Chen C; Chen LY; Pan S
J Cell Mol Med; 2024 Feb; 28(3):e18084. PubMed ID: 38130025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
